Voy­ager's gene ther­a­py for Parkin­son's shows promise in ear­ly da­ta from small Phase Ib tri­al

Voy­ager Ther­a­peu­tics $VY­GR re­port­ed some good news from the front lines of its gene ther­a­py clin­i­cal tri­al in Parkin­son’s, show­ing the com­pa­ny’s drug might one day res­cue pa­tients from the in­evitable de­cline as­so­ci­at­ed with their re­sponse to lev­odopa.

Parkin­son’s, char­ac­ter­ized by low dopamine lev­els in the brain, pro­gress­es over time with the pa­tient ex­pe­ri­enc­ing a de­bil­i­tat­ing loss of mo­tor and non-mo­tor func­tions – with symp­toms like trem­bling, slow­ing of move­ments, and im­paired bal­ance. As the dis­ease pro­gress­es, these symp­toms be­come more se­vere, re­sult­ing in pe­ri­ods of de­creased func­tion in the pa­tient, al­so called “off” time. Thanks to ex­ces­sive dos­es of lev­odopa aimed at treat­ing the “off” time, some pa­tients ex­pe­ri­ence in­vol­un­tary move­ments, or dysk­i­ne­sia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.